Startup profile · funding coverage
Samphire Neuroscience funding, valuation and investors
Wearable neurotechnology focused on women's menstrual health.
Verified company research · funding, investors and latest developments
Keep track of Samphire Neuroscience
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
$5M · June 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$7.3M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · London, United Kingdom
Investors in latest funding
Lead: Fortify Ventures , Inventure
Other: Ayuh Ventures , APEX , SOSV , Afterwork Ventures , FIRSTPICK , Seaside Ventures
Overview
Samphire Neuroscience develops wearable brain-stimulation technology for women's health. Its Nettle device is designed around menstrual-related mood and pain symptoms. The company announced a $2.3 million pre-seed financing in February 2024 and a $5 million seed financing in 2025. Ayuh Ventures was named in both rounds. Funding figures describe the entire rounds; Ayuh's individual investment was not disclosed.
Why Samphire Neuroscience is interesting
Samphire brings medical-device development to an underserved health category. Its commercial progress depends on clinical evidence, regulatory permissions, patient access and distribution, alongside the practical usability of the wearable.
Product & use cases
Nettle is a head-worn neuromodulation device. Samphire's company history describes UK and EU Class IIa medical-device clearance. The 2025 financing announcement said capital would support commercialization and further clinical development. Regulatory permissions and approved uses vary by market.
- Development of wearable approaches to menstrual-related symptoms.
- Clinical and distribution partnerships in women's health.
Key facts
- Ayuh named in the 2024 pre-seed and 2025 seed announcements.
- The 2025 seed was co-led by Fortify Ventures and Inventure.
- Company describes Nettle's UK and EU Class IIa clearance; no US approval is implied.
Funding history (newest first)
Seed
2025-06 $5M- Fortify Ventures (lead)
- Inventure (lead)
- Ayuh Ventures (participant)
- APEX (participant)
- SOSV (participant)
- Afterwork Ventures (participant)
- FIRSTPICK (participant)
- Seaside Ventures (participant)
Pre-Seed
2024-02 $2.3M- Ayuh Ventures (participant)
- SOSV (participant)
- FIRSTPICK (participant)
- Afterwork (participant)
- Seaside (participant)
- CVX Ventures (participant)
Source: Read source · firstpick.vc
Investors in our directory
Funds linked from Samphire Neuroscience's profile — open a fund page for stage focus and related deal articles.
Industries
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Samphire Neuroscience
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.